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It is now well known that gene expression is intricately regulated inside each cell especially
in mammals. There are multiple layers of gene regulation active inside a cell at a given
point of time. Gene expression is regulated post-transcriptionally by microRNAs and other
factors. Mechanistically, microRNAs are known to bind to the 3’ UTR of mRNAs and
cause repression of gene expression and the number of known microRNAs continues
to increase every day. Dysregulated microRNA signatures in different types of cancer are
being uncovered consistently implying their importance in cellular homeostasis. However
when studied in isolation in mouse models, clear-cut cellular and molecular mechanisms
have been described only for a select few microRNAs. What is the reason behind this
discrepancy? AremicroRNAs small players in gene regulation helping only to ﬁne tune gene
expression? Or are their roles tissue and cell type-speciﬁc with single-cell level effects on
mRNAexpression andmicroRNA threshold levels? Or does it all comedown to the technical
limitations of high-throughput techniques, resulting in false positive results? In this review,
wewill assess the challenges facing the ﬁeld and potential avenues for resolving the cellular
and molecular mechanisms of these small but important regulators of gene expression.
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BACKGROUND
microRNAs (miRNAs) are short single stranded RNAs that reg-
ulate mRNA expression at the post-transcriptional level. The
very ﬁrst miRNA:mRNA target pair was discovered in the labs
of Victor Ambros and Gary Ruvkun (lin-4 and lin-14, respec-
tively) who were studying the regulation of developmental timing
in C. elegans (Lee et al., 1993; Wightman et al., 1993). The
mature miRNA is a single stranded ∼22 nucleotide RNA that is
sequentially processed from a primary transcript (pri-miRNA)
and the resulting stem cell loop structure (pre-miRNA) by the
proteins Drosha and Dicer respectively (Kim et al., 2009). The
basic principle of miRNA mediated regulation- that miRNAs tar-
get mRNAs for repression by binding to the latter’s 3’UTR- was
recognized in these early studies, but the pervasiveness of this
mechanism in gene regulation was not recognized until much
later. The number of miRNAs in humans and mice is con-
stantly being revised, and it is likely that much of the genome is
under the control of miRNA-mediated gene expression regulation
(Kim et al., 2009).
Dysregulation of miRNAs has been observed in a number of
diseases, especially hematopoietic malignancies like chronic lym-
phocytic leukemia (CLL) and epithelial malignancies such as lung
cancers and breast carcinomas (Calin and Croce, 2006). However,
the exact cause-effect mechanism has not been established for
many miRNAs and diseases despite signiﬁcant efforts into such
research. Indeed, while numerous cancer-causing or promoting
miRNAs have been proposed on the basis of their dysregulation
in disease states, few have been established as truly oncogenic or
tumor suppressive. Implicit in this observation is the question
of whether we should be interpreting the roles of miRNAs in
disease states in the same way we evaluate the role of proteins
in oncogenesis, and what molecular and cell biological mecha-
nisms distinguish miRNAs as novel factors in disease causation
and progression. In this review, we will evaluate these questions
critically, using hematologic cancers as an example. We specu-
late that the paucity of deﬁnitive experimental evidence is likely
attributable to a combination of several factors- including, but
not limited to, the inherent genetic redundancy of miRNAs, non-
genetic heterogeneity of cells and our technical limitations in small
RNA proﬁling. We begin with a brief primer on the complexity of
miRNA based regulation and then examine research ﬁndings with
the aim of understanding the limitations of current strategies to
study miRNAs and exploring alternatives for the future.
GENERATING COMPLEXITY: HOW THE BIOLOGY OF miRNAs
IMPACTS INTERPRETATION OF PHENOTYPES
miRNA biogenesis and mechanism of action have been exten-
sively studied and detailed mechanisms are reviewed elsewhere,
but we review some of the mechanisms whereby complexity in
gene regulation may be generated by miRNAs (Kim et al., 2009;
Krol et al., 2010). The gene structure of miRNAs is the ﬁrst source
of complexity. Brieﬂy,miRNAs can be encodedwithin an exon of a
unique transcript, can occur as “polycistronic”miRNAs, or can be
found within the introns of protein-coding or non-coding genes.
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The primary transcript undergoes endoribonucleolytic cleavage
by Drosha/DGCR8 in the nucleus, and then in the cytoplasm.
Intronic microRNAs (mirtrons) have also shown to be generated
by a non-Drosha/DGCR8 mediated, Dicer only dependent mech-
anism (Castellano and Stebbing, 2013). Only one of the strands
(the guide strand) thus generated is incorporated into the RNA
induced silencing complex (RISC). Although the passenger strand
is usually degraded, there are now reports emerging that show
an important role for the passenger strand in gene regulation
(Almeida et al., 2012; Epis et al., 2012; Uchino et al., 2013). The
two strands of the microRNA are termed 5p and 3p depending
on their orientation. Recent reports suggest that incorporation
of either strand into the RISC complex is possible. Examples
include miR-142 and miR-17 where incorporation of both the
strands into the RISC complex occurs, leading to the presence of
both 5p as well as 3p transcripts inside the cell (Kasashima et al.,
2004; Yang et al., 2013). This introduces yet another layer of reg-
ulation since the 5p and 3p microRNAs would target different
genes because of the difference in their seed sequence. This is the
case with miR-28 where overexpression of miR-28-5p and miR-
28-3p caused different effects in colorectal cancer cells (Almeida
et al., 2012). Interestingly, miR-17-5p as well as miR-17-3p were
shown to target the same gene TIMP3 and induced prostate can-
cer growth (Yang et al., 2013). All of these steps are subject to
regulation and can therefore create intricate patterns of miRNA
expression.
Once the miRNA is incorporated into RISC, it causes repres-
sion of target gene expression. miRNAs usually target the 3’UTR
(untranslated region) of the mRNA. Perfect complementarity
between the miRNA and its target leads to destruction of the
RNA by the “slicer” activity in the Argonaute-2 protein which
is part of the RISC (Meister, 2013). This type of repression is
called RNAi and is very rare in mammals but more commonly
seen in plants. More commonly, incomplete complementarity
between the miRNA and its target is seen leading to transla-
tional repression. Proposed mechanisms include interference of
the miRNA with the formation of a looped mRNA structure
required for optimal translation, but further study is needed (Kim
et al., 2009). Nonetheless, the net effect of miRNA expression
is thought to be repression of the target gene. The repression
is thought to be limited in extent (i.e., the gene is partially
repressed) because miRNAs are induced and degraded over
time.
Although binding to the 3’UTR and repression of the gene
is considered to be the current canonical pathway for miRNA
mediated gene regulation, non-canonical binding and targeting
has also been described for microRNAs. Some microRNAs have
been shown to target the promoters of genes and cause either
gene activation (miR-373, miR-744, miR-1186) or gene repres-
sion (miR-320, miR-373). Gene activation was accompanied by
the presence of active histone marks (H3K4 trimethylation) while
gene repression was caused by a closed chromatin structure due
to H3K9 dimethylation (Huang and Li, 2012). Recently, CLASH
(cross-linking, ligation, and sequencing of hybrids) was used
along with overexpression of an Ago1 fusion protein and high-
throughput sequencing to map the miRNA-interactome. This
revealed that even though the majority of the miRNA binding
sites were in the 3’UTRs, microRNAs also bound to 5’UTRs, gene
bodies, long non-coding RNAs (lncRNAs) as well as introns. There
was also a class of microRNAs whose mRNA interactions did not
involve the seed region (miR-92a), or so-called “seedless binding”
(Helwak et al., 2013).
The temporal patterns of miRNA expression add signiﬁ-
cantly to the complexity of the problem. Some miRNAs are
strongly induced by stimuli such as LPS (miR-155; O’Connell
et al., 2009) whereas others are expressed at baseline levels and
seem to maintain fairly constant levels during developmental
processes (Pauli et al., 2011; Guan et al., 2013). In addition
to their biogenesis, which can be regulated transcriptionally
and post-transcriptionally at the level of RNA processing (van
Kouwenhove et al., 2011), their degradation can be regulated both
by proteins, as is the case with Xrn2 (Grosshans and Chatter-
jee, 2010), and by cell divisions, which dilute out the pool of
miRNAs if their rate of production is less than the sum of dilu-
tion and degradation. As one considers disease-related changes
in miRNA expression, understanding the temporal expression
pattern, particularly whether phenotypes may be induced by
various biological stimuli, impacts the interpretation of pheno-
typic changes. As an example, miR-155-deﬁcient mice showed
normal baseline levels of B-cells and T-cells, but these mice
clearly had major defects in immune responses (Thai et al.,
2007; O’Connell et al., 2010b; Huffaker et al., 2012). It is clear
that miR-155 has major functions when induced, and that
these functions have importance in the context of oncogene-
sis.
Adding to the complexity of miRNA mediated repression is
computational and experimental evidence that a single miRNA
can target hundreds or potentially thousands of mRNA molecules.
The stoichiometry of such inhibition is incompletely understood,
and it would seem that any two targets could be inhibited to differ-
ent degrees by a given miRNA. Given computational algorithms
that are imperfect and the lack of a methodology to predict the
magnitude of repression, both the identity of and extent of effect
on target gene expression have to be deﬁned in an individual fash-
ion by experimentation. Hence, it would be extremely difﬁcult to
predict the effects of miRNA expression on gene expression at the
global level.
Post-transcriptional gene regulation by miRNAs is further
modulated by RNA binding proteins (RBPs). Numerous RBPs
have recently been characterized recently and many play a role
in mRNA stability. A target mRNA can be competitively bound by
a RBP and a miRNA, leading to a reduction in repression levels
by the miRNA. RBP binding can also cause a switch in mRNA
secondary structure, causing steric hindrance to miRNA binding.
One example is the binding of IGF2BP1 (Insulin like growth factor
2 binding protein 1) to the BTRC and MITF mRNAs, preventing
the binding of microRNAs 183 and 340 respectively. This leads to
de-repression of these genes and subsequent downstream effects
(Elcheva et al., 2009; Goswami et al., 2010; van Kouwenhove et al.,
2011).
Lastly, there is a consideration about miRNA-based regulation
that seems obvious but has important implications. miRNAs can
only target transcripts that have been induced in a particular devel-
opmental or pathological context; they cannot, a priori, cause a
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gene to be expressed. Hence, the set of genes that a miRNA reg-
ulates in a given cell is highly dependent on the transcriptional
program of that particular cell. Finding functional targets in one
cell type does not necessarily implicate the same targets in a dif-
ferent cell type. Similarly, signaling pathways implicated in one
cell type may not be operant in a different cell type. This has
been highlighted by the germline knockout of miR-146a, which
demonstrated a phenotype that was almost exclusively restricted
to the hematopoietic system (Boldin et al., 2011; Zhao et al., 2011).
This has important implications for how one predicts the effects
of miRNA manipulation across different tissue types.. This also
emphasizes the fact that microRNA targets will most probably be
tissue type speciﬁc. SomicroRNA:mRNA interaction studies need
to be performed speciﬁc to cell types and their results interpreted
according to the tissue of origin.
miRNAs AND CANCER: PROFILING STUDIES
After the recognition of miRNAs as being widespread in the
genome of humans, there was a keen interest to identify dysreg-
ulated miRNA proﬁles in a number of diseases, especially cancer.
Altered miRNA proﬁles were indeed found in many cancers (Calin
and Croce, 2006). For example miR-21 was found to be up reg-
ulated in a number of malignancies like glioblastomas, breast,
colon and pancreatic cancer and has been anointed as an onco-
genic miRNA (Garzon et al., 2009). The miR 17–92 cluster was
up regulated in lymphomas and in breast, lung, colon, stom-
ach, and pancreatic cancers (Calin and Croce, 2009; Garzon et al.,
2009).MiR-155 was found to be highly expressed in certain types
of B-cell lymphomas, including CLL with an aggressive course and
diffuse large B-cell lymphoma (Calin et al., 2004; Eis et al., 2005;
Chen et al., 2008). Numerous other miRNAs have also been iden-
tiﬁed in patient-based samples as being dysregulated in disease
states.
Similarly, some miRNAs are down regulated in tumors and
are therefore classiﬁed as tumor suppressor miRNAs. The classic
examples include miR-15a and miR-16-1 loss in CLL and multiple
myeloma, let-7 miRNA loss in lung and breast cancers (Garzon
et al., 2009). miR-34 is a p53 responsive miRNA family and its
members, notably miR-34a, have been observed to be lost in pan-
creatic, colon, breast and liver cancers, and is a predictor of poor
prognosis in CLL (Chim et al., 2010; Christoffersen et al., 2010;
Corney et al., 2010; Hermeking, 2010; Choi et al., 2011; Fabbri
et al., 2011). In myelodysplastic syndrome, miR-146a was down-
regulated, and at least part of the time, this occurs as a consequence
of deletion of the long arm of chromosome 5 in the malignant
hematopoietic progenitor cells (Starczynowski et al., 2010; Boldin
et al., 2011; Zhao et al., 2013).
The last 10 years have seen a proliferation of miRNA proﬁling
studies, and while many miRNAs are dysregulated at the level of
their expression, it is unclear how miRNAs become downregu-
lated in speciﬁc cancers. Until recently, the chromosomal deletion
of miR-15a/16 (chromosome 12p) and miR-146a (chromosome
5q) comprised the only two recurrent genetic abnormalities that
can be traced as a direct cause for miRNA downregulation in the
hematopoietic system and as noted below, in cancer pathogene-
sis. Earlier last year, whole genome sequencing of de novo acute
myeloid leukemia (AML) revealed that miR-142 undergoes point
mutations, potentially resulting in loss of targeting by the 3p form
(Cancer Genome Atlas Research Network, 2013). Further work
has shown that miR-142 mutations in AML are localized to the
seed region of miR-142-3p, leading to reduced expression of miR-
142-5p. It is an interesting case where the stability of one form of
the miRNA is dependent on the other form (Trissal et al., 2013).
Other possible mechanisms include dysregulated miRNA expres-
sion resulting downstream of mutations in transcription factors.
Since epigenetic studies of gene expression regulation have largely
focused on protein-coding genes (where rules for histone modiﬁ-
cations are better understood), annotations of miRNA promoters
and enhancers have lagged behind those in the protein-coding
genes. Therefore, further work in elucidating mechanisms of
miRNA dysregulation and their integration into large scale genetic
networks that are dysregulated in cancer is required.
miRNAs: SMALL PLAYERS IN PATHOGENESIS?
As expected, alteredmiRNAproﬁles have been observed in numer-
ous malignancies. However, there are only a few malignancies
where a causal relationship has been directly established for the
dysregulation of the miRNA and tumor development. A general
role for the miRNA pathway in oncogenesis was established by
the observation that mice heterozygous for Dicer developed an
increased incidence of tumors (Kumar et al., 2009; Ravi et al.,
2012). Hence, global abnormalities in miRNA expression are
indeed causally linked to an increased incidence of tumors.
Among thewell-knownoncomiRs, overexpressionof miR-21 in
mice caused pre-B cell leukemia/lymphoma (Medina et al., 2010).
In this study, miR-21 was expressed in a Nestin-Cre-inducible
manner, surprisingly producing B-cell tumors. miR-155 over-
expression led to a lymphoproliferative disorder in B-cells and
eventually acute lymphoblastic lymphoma/leukemia (ALL), and
myeloproliferative disease when overexpressed in myeloid cells
(Costinean et al., 2006, 2009; O’Connell et al., 2011; Babar et al.,
2012). Recently, overexpression of miR-22 in hematopoietic cells
has been shown to lead to MDS (Song et al., 2013). Ectopic expres-
sion of miR-29a (Han et al., 2010) and enforced expression of
miR-125b in hematopoietic stem cells (HSCs) led to a myelo-
proliferative disorder which progressed to AML (O’Connell et al.,
2010a; Chaudhuri et al., 2012). Overexpression of the miR-17-19b
cluster (ﬁve miRNAs) in the bone marrow of Eμ-Myc transgenic
mice led to an acceleration of lymphoma development (He et al.,
2005). Recently, B-cell speciﬁc overexpression of the miR 17–92
cluster led to lymphoma development, establishing its role as an
independent oncogene (Jin et al., 2013). Other miRNAs which are
highly expressed in tumors however, have failed to recapitulate the
full tumor phenotype. For example, overexpression of the puta-
tive oncogenic miR-25-106b-93 cluster in mice showed no tumor
development.
Deletions of tumor suppressor miRNA in mice have to date
yielded phenotypes with a long latency. Deletion of the tumor
suppressor miRNA cluster, encoding miR-15a and miR-16-1 led
to a CLL like disease in mouse models, albeit at around 18 months
of age and only in∼30% of the involved mice (Aqeilan et al., 2010;
Klein et al., 2010). Deletion of the miRNA-146a led to a myelo-
proliferative phenotype and hematologic malignancies, again late
in life (∼18 months; Boldin et al., 2011; Zhao et al., 2011). Mice
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with targeted deletions of the following putative tumor suppres-
sor miRNAs did not show development of an overt malignancy:
miR-145, miR-223, miR-133, and miR-206 (Park et al., 2010).
Although the overexpression of miR-29 had been shown to reduce
liver cancer growth in mice (which is contrary to the role that
it plays in the hematopoietic system), knockout of the miR-29
locus led to liver ﬁbrosis and not any overt malignancy (Xiong
et al., 2010; Roderburg et al., 2011). Perhaps the most surprising
example of a knockout lacking a phenotype is the miR-34a knock-
out mouse, which did not develop any overt malignancies despite
being downstream of arguably the most important tumor sup-
pressor in the human cell, p53. Indeed, the triple knockout of all
three members of miRNA family did not lead to an increase in
cancer incidence (Concepcion et al., 2012). This is despite the fact
that miR-34a targets numerous transcripts for proteins important
in cell cycle progression, cell cycle progression, and oncogenesis
(Siemens et al., 2013).
From a therapeutic standpoint, overexpression and in vivo
delivery of miRNAs/ modiﬁed small nucleic acid molecules has
met with some success. The overexpression of tumor suppres-
sor miRNAs have been discovered to be successful in delaying
tumor development or reducing the tumor burden in mouse
models. Examples include miR-34a (lung adenocarcinoma), miR-
145 and miR-33 (colon carcinoma) and miR-15 and 16-1 (colon
carcinoma). Systemic delivery of the tumor suppressor let-7
increased the latency to lung cancer in mouse models (Croce,
2009; Nana-Sinkam and Croce, 2013).There are also some in vivo
studies where knock down of oncomiRs has helped in atten-
uating tumorigenesis. In a mouse model of Ras-driven lung
cancer,miR-21 inhibition slowed tumor progression (Hatley et al.,
2010). Administration of antagomiRs in mice to block miR-10b
and miR-223 resulted in signiﬁcant antitumor activity against
breast carcinoma and hepatocellular carcinoma respectively
(Garzon et al., 2010).
In essence, not all dysregulated miRNAs discovered by expres-
sion proﬁling of tumors are pathogenetic and many do not have a
clear mechanism of action in oncogenesis. In general, cancer phe-
notypes driven by overexpression seem to be more severe than
those generated by loss-of-function, and the latter seem to be
highly age dependent. These ﬁndings may be explained by the
fact that miRNAs can only act on a “pre-existing” transcriptional
program. Hence, miRNA gain of function in a cell type could
lead to aberrant functions by targeting genes that are not normally
repressed, while loss of function would only affect cells where the
appropriate target genes and the miRNA of interest are concur-
rently expressed. This again brings forward the idea that miRNA
gain and loss-of-function should be studied in the appropriate sys-
tem and the appropriate biological context. One should also bear
in mind the fact that microRNA overexpression or knockdown
phenotypes have little utility in the absence of human disease
speciﬁc dysregulation. Hence animal models and human stud-
ies should be used together to unravel the mechanism behind
dysregulated miRNAs.
miRNA PROFILING: USEFUL BUT NOT FOOLPROOF
Proﬁling of tumors provides patient-based data onmiRNAexpres-
sion patterns, which is undeniably important, but this presents
its own set of problems. Centrally, it is very difﬁcult to control
for variability in collection of tumor cells between patients, as
opposed to the ease of collecting high-quality controlled samples
under experimental conditions. While it seems that miRNAs are
better preserved between samples, as small RNAs demonstrate
more stability than long RNAs, the techniques used to detect
miRNAs also engender some variability. The common techniques
for high-throughput proﬁling include microarrays, RNA-Seq and
qPCR arrays. Cost and ease of data analysis remain the two
main criteria which determine the type of platform utilized.
The gold standard for individual miRNA detection remains the
Northern blot and for samples with a low RNA yield (patient
samples), reverse transcriptase (RT)-qPCR is the technique of
choice for miRNA quantitation (Pritchard et al., 2012). How-
ever, interpretation of fold changes obtained from RT-qPCR
experiments should always consider absolute levels of miRNA
expression in control cells. For example, the biological impact
of a 10-fold increase of a low expressed miRNA (1 molecule
per cell increases to 10 molecules per cell) may be less sig-
niﬁcant than a 1.5-fold increase of a highly expressed miRNA
(50,000 molecules per cell to 75,000 molecules per cell), depend-
ing on the relative expression levels of their mRNA targets. A
last consideration in qPCR is the use of appropriate normaliza-
tion techniques, investigators should consider the use of multiple
reference genes or mean expression value of all expressed microR-
NAs in a sample as a normalization factor (Mestdagh et al.,
2009).
Technically, both the RT step and the amount of RNA can be a
source of signiﬁcant bias during RNA proﬁling. A study compar-
ing the efﬁciency of different types of RT enzymes showed around
a 100-fold difference between enzymes for some genes (Stahlberg
et al., 2004). This effect was particularly pronounced for mRNAs
whose expression is low. Introduction of errors due to secondary
structure, differences in priming efﬁciency and properties of the
enzyme itself (like RNAse H activity) can all inﬂuence the product
yield from the RT reaction. Also some miRNAs are GC rich and
have a higher Tm which is a reason for reduced reverse priming
efﬁciency and consequently smaller representation in the cDNA
library. This effect will bemuchmore pronouncedwhen the quan-
tity and quality of the RNA is low (for example, parafﬁn embedded
samples). Similar to the RT reaction, each reaction in the sample
preparation workﬂow may lead to variations including the adap-
tor ligation step using RNA ligase, linear ampliﬁcation step as well
as the ﬂuorochrome labeling step for microarrays (Stahlberg et al.,
2004; Baker, 2010).
With so many commercial options available for miRNA proﬁl-
ing, it is somewhat alarming that different groups have reported
poor reproducibility across these different platforms. To avoid this
problem, it has been suggested that once a certain proﬁlingmethod
has been standardized in the lab, maintaining the same technique
is advisable to eliminate bias across methods (Git et al., 2010).
Earlier quality control studies showed a big variation in the pro-
ﬁling of miRNAs by high-throughput sequencing especially when
the quantity of transcripts was not abundant. However, encourag-
ingly, recent reports onquality control of RNA-sequsingnewer kits
suggests that current platforms are reproducible and comparable
across each other (Adiconis et al., 2013).In addition to the range of
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platforms, data analysis can differ signiﬁcantly between studies as
well as labs, particularly in the stringency of false discovery rates
and in the numerical level of difference between the samples. This
too could contribute to the seemingly disparate results obtained
by different groups.
Apart from these technical considerations, other factors may
also lead to difﬁculty in fully understanding miRNA expression
data. For example, gene duplications have led to miRNAs origi-
nating from different chromosomal loci, and each locus is subject
to unique regulation. At present, we can only quantify the total
amount of mature miRNA being produced because routine pro-
ﬁling studies do not distinguish which locus they originated from.
Moreover, researchers have identiﬁed so-called IsomiRNAs, which
are miRNAs that differ from their cognate miRNA by a few
nucleotides either at the 3′ or even the 5′ end. The presence of
IsomiRNAs could certainly cause a bias in mature miRNA quan-
titation by these high-throughput methods (Vickers et al., 2013).
Hence, factors intrinsic to the roles of miRNAs in cells can cause
variability in data generated by high-throughput studies.
Several proposals have been made to improve technical issues
with miRNA based proﬁling techniques. Some laboratories
have advocated the use of external reference samples for the
exact quantitation of miRNAs (Git et al., 2010). But these ref-
erence samples do not mimic conditions inside the human
body: most importantly, total RNA samples probably contain
less than 0.01% miRNA (Git et al., 2010). There is ribosomal
RNA, tRNA and mRNA that could compete for binding with
preparative enzymes and thereby could potentially affect results.
This is being negated to a certain extent now by removing
the abundant ribosomal RNA before using the RNA for pro-
ﬁling (Git et al., 2010). It would be ideal if guidelines similar
to the MIQE guidelines (minimum information for publication
of quantitative real-time PCR experiments) were made avail-
able for miRNA proﬁling techniques (Bustin et al., 2013). This
would ensure better experimental practice allowing more reliable
comparative analysis of miRNA proﬁling data (Witwer, 2013).
Hence, having a carefully curated database using uniform ana-
lytic techniques would go a long way toward removing obstacles
that confound efforts to jump from proﬁling studies to func-
tional analyses characterizing dysregulated miRNAs in cancer
states.
Apart from high-throughput RNA sequencing, other novel
techniques are also being employed to delineate targets of
microRNAs. One of these is cross-linking immunoprecipitation-
sequencing (CLIP-seq), where small RNAs and mRNAs bound to
one of the proteins in the RISC, usually Ago-1, are cross-linked
by ultraviolet radiation, pulled down using an anti-Ago1 anti-
body and then sequenced (Mittal and Zavolan, 2014). RISC-seq
is a method similar to CLIP-seq using anti-Argonaute antibody
pull-down followed by reverse transcription and sequencing. The
difference here is the absence of any cross-linking (Matkovich
et al., 2011). As mentioned previously, CLASH utilizes a similar
cross-linking technique but ligates the miRNA and the mRNA
using RNA ligase. While the speciﬁcity of CLASH is high, its sen-
sitivity is reported to be very low (∼2%; Helwak et al., 2013).
The usage of these techniques in parallel with gene expres-
sion analyses in the setting of miRNA gain- or loss-of-function
will likely increase the speciﬁcity of the observed microRNA
targets.
miRNAs AND REDUNDANCY
Here, we turn to some possible reasons as to why we see small
phenotypes in miRNA deﬁcient mice. The ﬁrst of these relates to
redundancy of both miRNAs and targeting of particular mRNAs
by different miRNAs. In addition to there being multiple genomic
loci producing the samemiRNA,manymiRNAs are part of miRNA
“families,” which target the same seed sequence. Hence, there is a
great deal of redundancy at the genomic level. Because the seed
sequence is small, a single miRNA can target a large number of
mRNAs (Thomson et al., 2011). The opposite is also true, that a
single mRNA can be targeted by numerous miRNAs, including
those from different families.
There are a number of miRNA target prediction tools avail-
able online including but not limited to TargetScan, PicTar, and
Miranda (Ritchie et al., 2013). Conﬁrmation of direct miRNA tar-
geting of mRNA is usually done by a luciferase reporter-3′UTR of
themRNAconstruct andoverexpressing themiRNA.However, not
all of the predicted mRNA targets are actual targets of the miRNA.
So what factors decide whether a miRNA will target a particu-
lar mRNA? There are many factors which likely play a role beyond
seedmatching and binding of complementary RNA strands. These
may include structural accessibility of the 3′UTR of the mRNA to
miRNAs, epigenetic modiﬁcations in targeted region preventing
miRNA binding and the presence of miRNA sponges called com-
peting endogenous RNAs (ceRNAs) which preferentially bind to
miRNAs thereby de-repressing their mRNA targets (Karreth and
Pandolﬁ, 2013). The prediction of miRNA-deﬁcient phenotypes
suffers from this lack of predictability of target repression.
Knocking out a single genetic locus encoding amiRNAmay not
be sufﬁcient to fully understand the function of a given miRNA.
Conceptually, this is similar to the situation of genetic redundancy
seen with protein-coding genes, but it is different because miRNAs
aremost commonly found as families, and themajority of miRNAs
share seed sequences with other microRNAs. Another important
thing to note is the unperturbed levels of themiRNA in a particular
tissue type. For example, miR-122 has been shown to account for
nearly 50% of the total hepatocyte miRNA pool. In this situation,
one could imagine that a knockout would have signiﬁcant effects
on gene expression (Szabo and Bala, 2013).
An ideal loss-of-function study will concurrently target all
redundant miRNAs for deletion. This requires a large amount
of resources to generate conventional knockout mice, which can
be prohibitive to undertake such a project. However, with the
advent of novel knockdown technologies like ZFNs (zinc ﬁn-
ger nucleases), CRISPRs (clustered regularly interspaced short
palindromic repeats) and TALENs (transcription activator-like
effector nucleases), these complicated knockout animals may now
be more feasible to create and study (Gaj et al., 2013). Alter-
native and novel approaches, such as designing ceRNAs that
can target entire families of miRNAs, should also be consid-
ered and carefully examined. This approach could provide a
viable method to knock down a large number of miRNAs at
the same time. Lastly, the role of speciﬁc miRNA-target interac-
tions should be carefully studied in carefully selected systems. In
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certain cases and in certain developmental/ pathologic contexts,
a single miRNA-target pair may be of paramount importance
(Xiao et al., 2007; O’Connell et al., 2009; Xiao and Rajewsky,
2009; Rao et al., 2010). Such interactions should be further
studied using targeted mutations of the miRNA binding site
in 3’UTRs, as described for miR-155 and AID (Borchert et al.,
2011).
In most currently utilized techniques, the extent of overexpres-
sion is usually higher than physiologically attainable limits. Such
overexpression may overwhelm the miRNA processing machin-
ery and cause off-target effects (Singh et al., 2011; Karlsen and
Brinchmann, 2013). Hence, some of the phenotypes that have
been elaborated with overexpression may be more striking simply
because of the extent of overexpression. Usage of endogenous pro-
moters which are weaker than the conventional ones or using an
inducible promoter which follows linear kinetics would be ideal,
but this remains technically challenging. Yet, many of these exper-
iments have revealed the central importance of miRNAs in driving
oncogenesis.
NON-GENETIC VARIATION AND THE THRESHOLD EFFECT
Recent studies have examined the role of variability of gene expres-
sion in the generation of different cell types during differentiation,
and presumably similar mechanisms are operant in cancer cau-
sation and progression. Even when a tissue contains cells of
the same type, the expression of a particular protein can show
stochastic cell-to-cell as well as temporal ﬂuctuations within the
same cell. Sometimes these ﬂuctuations were up to ∼1000-fold
between the low expressing and high expressing cells at one point
of time (Chang et al., 2008). These differing gene expression levels
might be purely stochastic or represent phenotypic variants within
the same population (Mukherji et al., 2011). Recent reports sug-
gest that such non-genetic heterogeneity might be generated by
miRNA-mediated effects on gene expression, and that this may
depend on the number of miRNA binding sites in the 3’UTR, the
level of mRNA in the cell as well as the level of miRNA in the
cell.
It has been demonstrated that at a constant level of miRNA,
there is a particular threshold of mRNA below which the repres-
sion by the miRNA is dramatically increased (Mukherji et al.,
2011). On the opposite end of the spectrum, past a certain
concentration of mRNA, miRNA-mediated repression is virtu-
ally ineffective. Similarly when the number of binding sites in the
3’UTR for the miRNA was increased from 1 to 7 in the UTR, the
repression increased by 40-fold (Chang et al., 2008). This thresh-
old effect between the miRNA and the mRNA is reminiscent of
biochemical precipitation reactions involving antigen- antibody
interactions at the optimum concentration of both the antigen as
well as the antibody. The precipitin line forms only at this zone
of equivalence and neither in the region of antigen excess nor in
antibody excess (Hornbeck, 2001). Hence, there are several rela-
tionships between the miRNA and mRNA that can profoundly
change the distribution of gene expression within a population of
cells.
It is implied that a cell requires a particular level of mRNA
and miRNA to coexist for repression to occur. The net effect of
these threshold effects is that our conventional thinking about
miRNA- that they partially repress gene expression- may only
FIGURE1 | Cellular heterogeneity inmicroRNA levels:Hypothetical cell
groups (A,B) have the sameaveragenumber of a particularmicroRNAper
cell (average= 4). SNAextraction and qPCRof both these groups of cells
would give the samemicroRNAexpression in both groups. However, a closer
look at the twogroups shows a bimodal type ofmicroRNAexpression pattern in
groupA and a homogenous expression pattern in groupB.This cell to cell
difference inmicroRNA levelswhichmight lead to different downstreamgene
expression is often overlooked in the absence of single-cell studies.
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hold for intermediate concentrations of the miRNA and the target
mRNA. The implications for experimental science are important:
we have to be cognizant of the level of the target mRNA in the cells
that are being targeted for perturbation of the miRNA. In experi-
ments with miRNA overexpression or knock down, most groups
usually collect the RNA from an entire population of cells, reveal-
ing a snapshot of the average gene expression in the cells. This
certainly doesn’t tell us the entire story- different cells with differ-
ing unperturbed target mRNA levels would have different levels
of change, depending on the mRNA threshold (Figure 1). There-
fore, single-cell expression studies are necessary to study the cell to
cell variation in response to miRNAs. Recent reports have shown
that miRNA expression can be studied at the single-cell level using
microﬂuidics (Wu et al., 2013). This, coupled with lineage trac-
ing studies may help us understand how phenotypes develop in
miRNA-deﬁcient or overexpressing cells, both in development and
in disease. The threshold effect is an important consideration in
miRNA therapeutics- particularly against cancers. Overexpression
of miRNAs might be highly efﬁcient at repressing the expression
of a critical target mRNA in cells that express the target at the opti-
mum level (Figure 2). However cells with extremely high levels of
the target mRNA would escape repression, if the above-proposed
mechanisms are correct, and may even be selected for. In theory,
this could lead to the elaboration of a more aggressive cancer
following an initial remission. Hence, targeted therapy utilizing
small RNA molecules requires careful consideration of ranges of
target gene expression in the cancer cells.
CONCLUSION
The plethora of proﬁling experiments has to date yielded impor-
tant data about miRNA expression in primary human disease
states, but we suggest that these constitute a starting point for
disease-relevant studies. A major obstacle to understanding these
miRNAs in vivo is the resource set required to individually target
these miRNAs and miRNA-target pairs. However, it seems that
such detailed studies will be required to understand the roles of
these small RNAs in disease pathogenesis and for their utilization
as therapeutic interventions.
We have tried to provide an overview of some of the fac-
tors that we believe to be obstacles in moving miRNA research
from the bench to the bedside (or vice-versa). These include
technical difﬁculties and variations in high-throughput proﬁl-
ing studies between labs and across platforms. These could be
standardized in the future with rigorous quality control, bet-
ter kits and standard guidelines for sample preparation and
data analysis. The question of genetic redundancy in miR-
NAs calls for more complex mouse models which are also
foreseeable in the future. Non-genetic heterogeneity presents
a totally different question altogether. Sophisticated single-
cell expression studies of mRNA, miRNA and proteins are
FIGURE 2 | miRNA:mRNA interaction-the threshold effect:The level of
repression of gene expression is dependent on the levels of both the
mRNA as well as the microRNA present inside a particular cell. This
hypothetical ﬁgure assumes that the expression of mRNA X is important for
hematopoietic cell lineage determination with high, intermediate and low
levels leading to lymphoid, myeloid and erythroid lineage differentiation
respectively. Gene X is a known target of the microRNA miR-Y. These effects
would be missed if single-cell measurements of X and miR-Y were not
performed which reiterates the necessity for newer techniques and analyses
especially at the single-cell level.
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required to pave the way to decipher the actual role of
non-genetic variants present within what many researchers
have previously presumed to be homogeneous populations.
With the advent of more robust and reproducible proﬁl-
ing techniques, more sophisticated genetic manipulations in
model systems, and single-cell analytical advances, we antici-
pate a clearer understanding of miRNA roles in biology and
pathogenesis.
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